ACTOS associated with reduced risk of heart attack and stroke in individuals with type 2 diabetes Results presented at the 43rd Annual Conference of the European Association for the analysis of Diabetes demonstrate the power of ACTOS to reduce the risk of ischemic cardiovascular disease in individuals with type 2 diabetes viagra . ACTOS is an oral antidiabetic agent for type 2 diabetes owned by the thiazolidinedione course of medicines. This retrospective evaluation of case records from a big managed care database of sufferers with diabetes showed that therapeutic regimens that included ACTOS had been associated with reductions in the chance for stroke or myocardial infarction compared to non-thiazolidinedione therapies.
The company has initiated the procedure for filing for a similar orphan designation in European countries. ACT Biotech will maintain attendance at the ASCO annual meeting in June, 2010. (.. ACT Biotech’s Telatinib receives orphan drug designation from FDA for treatment of gastric cancer ACT Biotech Inc., a privately kept biotechnology company developing a portfolio of oral kinase inhibitors mainly because anti-cancer medicines, announced today that the business’s extremely selective oral kinase inhibitor, Telatinib, has received orphan medication designation from the U.S.